Aevi Genomic Medicine, Inc.
http://www.aevigenomics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Aevi Genomic Medicine, Inc.
Deal Watch: BMS Backs Out Of UniQure Gene Therapy Collaboration
The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.
Cerecor Turns The LIGHT Back On As Avalo, With PRV Haul In Sight
The former Cerecor boasts four pipeline assets that could yield US FDA priority review vouchers. Having divested CNS assets, the renamed firm will focus on IBD with first-in-class anti-LIGHT candidate, plus immunology and rare diseases.
Asia Deal Watch: Vibegron’s Vagabond Journey Continues With Eisai Acquiring Partial Asian Rights
Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio
Deal Watch: AstraZeneca Continues Divestments By Offloading US/Canada Seroquel Rights
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Medgenics Medical Israel Ltd.
- neuroFix Therapeutics, LLC
- Medgenics Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice